The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Ruvise (imatinib mesilate), 100 and 400 mg film-coated tablets. It was intended to be used for adults as add-on therapy for the treatment of pulmonary arterial hypertension (PAH).

The application for the marketing authorisation for Ruvise was submitted to the Agency on 29 February 2012. At the time of the withdrawal, the medicine was under review by the Agency’s Committee for Medicinal Products for Human Use (CHMP).  In its official letter, the company stated that it is withdrawing the application since additional data are required to address CHMP questions relating to the benefit-risk assessment of imatinib in PAH patients. These data will not be available within the timeframe allowed in the centralised procedure.

More information about Ruvise and the state of the scientific assessment at the time of withdrawal will be made available in a question-and-answer document. This document will be published on the Agency’s website after the CHMP meeting of 18-21 February 2013.

Notes: Withdrawal of an application does not prejudice the possibility of a company making a new application at a later stage.


Posted on the EMA website on 24 January 2013